Melissa R Junttila

7PUBLICATIONS
83CO-AUTHORS
Molecular targetsPredictive and prognostic markersMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 06, 2025
Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.

Melissa R Junttila, Claire E Repellin, Sumeet Salaniwal

|Aug 23, 2024
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.

Christopher T Chen, Vishesh Khanna, Shivaani Kummar

|Jan 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.

Wassim Abida, Andrew W Hahn, Neal Shore

|Sep 11, 2023
A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer.

M Dorso, Payal T Patel, Aleksandr Pankov

|Aug 19, 2022
EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS G12D tumor development and propagation.

Ariel Pribluda, Anneleen Daemen, Anthony Nelson Lima

|Oct 07, 2020
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.

Anneleen Daemen, Jonathan E Cooper, Szymon Myrta

Pageof 2

Frequent Collaborators

5 joint publications

Anneleen Daemen

3 joint publications

Edna Chow Maneval

3 joint publications

Pratik S Multani

3 joint publications

Aleksandr Pankov